July 5, 2025

FacebookTwitterInstagramYouTube
  • Home
  • Events
  • NEWS
    • Top Stories
    • National News
    • National Sports
  • Current Contests
  • Photos/Video
    • Photos
    • Videos
  • On-Air
    • Kat & Ku`ehu
    • G. Cruz
    • Kaohu James
  • Podcasts
    • KWXX Mauna Loa Eruption Updates
    • Island Conversations
    • COVID-19 Interview
  • Contact
  • Info
  • Search
  • FCC Applications
MENU
  • Home
  • Events
  • NEWS
    • Top Stories
    • National News
    • National Sports
  • Current Contests
  • Photos/Video
    • Photos
    • Videos
  • On-Air
    • Kat & Ku`ehu
    • G. Cruz
    • Kaohu James
  • Podcasts
    • KWXX Mauna Loa Eruption Updates
    • Island Conversations
    • COVID-19 Interview
  • Contact
  • Info
  • Search
  • FCC Applications

FDA issues second EUA for antibody treatment for COVID

November 21, 2020 at 8:32 pm sbracken
  • Blogs
  • Covid-19
  • Tweet
  • Share
  • Reddit
  • +1
  • Pocket
  • LinkedIn
regeneron-logo

The FDA has granted Emergency Use Authorization (EUA) to Regeneron Pharmaceuticals for casirivimab and imdevimab, administered together,  as a treatment for COVID-19. This is the same experimental monoclonal antibody treatment that President Trump received when he was hospitalized at Walter Reed Medical Center for COVID-19.

The treatment is designed to be used in patients 12 years or older, weighing at least 40 kilograms (around 88 pounds), who have mild to moderate COVID-19 but are in danger of it progressing to severe COVID-19.

The drugs must be given together via intravenous infusion.

In its press release, the FDA said “Casirivimab and imdevimab are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.”

On Nov. 10, the FDA issued an EUA to Eli Lilly, Inc., for the monoclonal antibody treatment bamlanivimab, for patients 12 years and older, weighing at least 40 kilograms, with mild to moderate cases of COVID-19.  Bamlanivimab must also be issued intravenously.

The challenge for health care providers for both IV treatments is to find places to administer the drugs where the patients could be monitored and not in close contact with patients receiving intravenous treatments for diseases like cancer, as those patients would be immune compromised and the concern was potentially exposing them to patients with COVID-19.

For more detail about the Regeneron drugs, click here.

Tags: COVID-19 treatment, monoclonal antibodies, Regeneron
Previous Story
State has 163 new COVID cases–isle has 15
Next Story
Roth names heads of Public Works, Planning, DEM

Facebook

Twitter

Tweets by KWXX

"Hawaii's Feel Good Island Music Radio Station"

Info

  • Home
  • Contests
  • Socialize
  • Contact Us
  • Station Info
  • EEO
  • FCC Public File (KWXX)
  • FCC Public File (KAOY)

National News

Sean “Diddy” Combs exiting the Crosby Street Hotel. Lower Manhattan NYC^ New York / USA - July 24^ 2019

Bail denied for Sean ‘Diddy’ Combs until sentencing on 2 lesser counts in se...

Paramount global logo on bright background. 3D render

Paramount reaches $16 million settlement in Pres. Trump’s ’60 Minutes’ law...

Social

Facebook Facebook Twitter Twitter Instagram Instagram YouTube YouTube
KWXX – Hilo, HI © 2025 Powered by OneCMS™ | Served by InterTech Media LLC
Are you still listening?
3628718253
Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)
702b405c7c2bf5d0f51af27bfe6a9275613033b7
1
Loading...